tbuckley/cabot-search huggingface dataset:
Changing patterns of hospital admission for asthma, 1981–97
Authors: D S Morrison, P McLoone
Journal: Thorax (2001)

BACKGROUND Hospital admission rates for asthma have stopped rising in several countries. The aim of this study was to use linked hospital admission data to explore recent trends in asthma admissions in Scotland. METHODS Linked Scottish Morbidity Records (SMR1) for asthma (ICD-9 493 and ICD-10 J45–6) from 1981 to 1997 were used to describe rates of first admissions and readmissions by age and sex. As a measure of resource use, annual trends in bed days used were also explored by age and sex. RESULTS There were 160 039 hospital admissions for asthma by 82 421 individuals in Scotland during the study period. The overall hospital admission rate increased by 122% (from 106.7 to 236.7 per 100 000 population) but this varied by sex, age, and admission type. First admissions rose by 70% from 73.2 per 100 000 in 1986 to 124.8 per 100 000 in 1997 while readmissions fell. Children (&lt;15 years) experienced a decline in overall admissions after 1992 due to falls in both new admissions and readmissions. By 1997 the ratio of female to male admissions was 0.57 in children, but 1.50 above 14 years of age. Mean lengths of stay fell from 10.7 days to 3.7 days between 1981 and 1997 and bed days used showed little change except for a decline after 1992 in children. CONCLUSIONS After a period of increasing hospitalisation for asthma in Scotland, rates of admission among children have begun to fall but among adults admissions continue to rise.
Low fibrinogen level: A predisposing factor for venous thromboembolic events with hormone replacement therapy
Authors: Maura K. Whiteman, Yadong Cui, Jodi A. Flaws, Mark Espeland, Trudy L. Bush
Journal: American Journal of Hematology (1999)

Several studies have reported an association between hormone replacement therapy (HRT) in postmenopausal women and increased risk of idiopathic venous thromboembolic events (VTEs). Given the widespread use of HRT, it is important to identify factors that may predispose women on HRT to VTEs. To address this concern, we examined potential risk factors for VTEs in women assigned to HRT in the Postmenopausal Estrogen/Progestin Interventions (PEPI) study, a three-year, double-blinded, placebo-controlled trial of 875 postmenopausal women designed to assess the effects of HRT on heart disease risk factors (HDL cholesterol, fibrinogen, blood pressure, and insulin). Women with a history of estrogen-associated VTEs were excluded from the trial. Ten women, all assigned to HRT, had a VTE during PEPI. Only baseline fibrinogen varied significantly between those who did (mean = 249.0 mg/dl) and did not (mean = 280.8 mg/dl) have a VTE while assigned to HRT (P < 0.03). Adjusting for covariates including age, smoking, body mass index, lipid levels, blood pressure, alcohol, exercise, and prior HRT or oral contraceptive use did not affect this finding. The significantly lower fibrinogen levels seen among women subsequently reporting VTEs may be a marker for a specific, but as yet undefined, coagulopathy that is magnified in the presence of exogenous hormones. However, larger studies are needed to confirm this finding. Am. J. Hematol. 61:271–273, 1999. © 1999 Wiley-Liss, Inc.
Highlights of the NCCN Oncology Research Program
Authors: Sarbajit Mukherjee, Karen Hicks
Journal: Journal of the National Comprehensive Cancer Network (2021)

This is an open-label, multicenter, phase II study of trifluridine/tipiracil (FTD/TPI) administered with oxaliplatin before chemoradiation in patients with adenocarcinoma of the esophagus or gastroesophageal junction (GEJ).Patients meeting inclusion criteria will receive 3 cycles of FTD/TPI (35 mg/m 2 twice daily) and oxaliplatin (85 mg/m 2 ) before undergoing concurrent chemoradiation (standard-of-care radiation dose of 5,040 cGy will be used at all participating study sites) with carboplatin (area under the curve, 2) and paclitaxel (50 mg/m 2 ) for 6 weeks, followed by surgery.FTD/TPI will be self-administered (in tablet form) twice daily by study participants and documented in the provided drug diary.In this study, circulating tumor DNA (ctDNA) levels will be collected at 5 different time points: at diagnosis, after completion of induction chemotherapy, after completion of chemoradiation, after surgery, and at the time of disease recurrence, if this occurs.The aim is to correlate the ctDNA level with disease recurrence and metabolic response on PET/CT.Accrual is expected to take 24 months (N545) with an additional 12 months of follow-up on study.After completion of 1 year of on-study follow-up, patients will be followed (monitored for survival status) as per standard of care: year 1 through year 2, every 3 to 6 months, every 6 to 12 months for 3 to 5 years, and then annually until disease progression or death, whichever occurs first.Estimated time frame for analysis of the primary endpoint is approximately 3 years after study commencement.
Clinical Neuroradiology
Authors: Bernard S. Wolf
Journal: JAMA (1966)

This text, originally published in German by Georg Thieme in 1960, now appears in an admirable English translation. The relatively small number of pages should not mislead one to believe that this is a modest endeavor. It is in fact a large volume with more than a thousand individual illustrations and 15 chapters. A chapter on radioisotope techniques has been added in the American edition. The title was selected to emphasize that "clinical symptoms constitute the starting point of the neuroradiological examination." However, the chapter headings, except perhaps for "The Epilepsies," do not pursue this theme. Each chapter is an independent monograph by acknowledged authorities. These include, beside the editor, Hermann Fischgold, Vernon H. Mark, Donald L. McRae, Jean Metzger, Herbert Schunk, Juan M. Taveras, Henry N. Wagner, and Oskar Wiedenmann. The authors do not hesitate to present their personal opinions based on extensive experience, and these opinions are the
THE VERDICT
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Animal Biology.
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical Education and State Boards of Registration
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 2214: Development and validation of PredicineATLAS, a 600-gene liquid biopsy panel for simultaneous detection of TMB and genomic alterations in Immuno-Oncology
Authors: Zhixin Zhao, Amy Chang, Tak Cheung, Feng Xie, Carlos Montesinos, Amy Xiaohong Wang, Kemin Zhou, Shidong Jia, JIanjun Yu, Pan Du
Journal: Cancer Research (2019)

Abstract Introduction: Tumor mutation burden (TMB) is a measurement of the number of somatic mutations carried by tumor cells. Microsatellite instability (MSI) reflects the genetic hypermutability. Both TMB and MSI have been shown to be effective genomic biomarkers for predicting response to anti PD-1/PD-L1 immunotherapy. Whole exome sequencing (WES) is a traditional means to estimate TMB and MSI from tumor tissue, however, it is challenging to translate it into blood or urine due to its high expense and low tumor cell percentage. In the present study, we developed a 600-gene liquid biopsy TMB panel, PredicineATLAS, to measure genomic alterations and estimate TMB and MSI using human body fluids. Methods: The PredicineATLAS panel contains 600 genes and covers 2.4Mb genomic regions (1.4 Mb of exonic coding regions). It was specifically designed for immuno-oncology, covering comprehensive immune- and cancer-related genes, biomarkers and MSI sites that are associated with anti PD-1/L1 therapy response. Reference materials with known genomic alterations and tumor cell lines were titrated with different concentrations to mimic different tumor contents for TMB and MSI measurement. Matched tissue and blood were used in validation study. Results: PredicineATLAS panel-based TMB strongly correlated with the WES-TMB using TCGA dataset. Analytical validation showed that PredicineATLAS NGS assay is highly robust and sensitive for detection of genomic alterations. Using matched tissue and blood sample set, blood-based PredicineATLAS panel-TMB and MSI correlate with its counterpart derived from tissue WES. Conclusions: PredicineATLAS liquid biopsy assay was developed and validated using reference materials and clinical samples. It detects genomic alterations and accurately estimate TMB and MSI, providing valuable genomic information to guide immuno-oncology therapy and clinical drug development. Citation Format: Zhixin Zhao, Amy Chang, Tak Cheung, Feng Xie, Carlos Montesinos, Amy Xiaohong Wang, Kemin Zhou, Shidong Jia, JIanjun Yu, Pan Du. Development and validation of PredicineATLAS, a 600-gene liquid biopsy panel for simultaneous detection of TMB and genomic alterations in Immuno-Oncology [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2214.
Mercury Exposure on School Bus
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cleveland Clinic
Authors: Marcia Glass
Journal: Annals of Internal Medicine (2020)

Ad Libitum1 September 2020Cleveland ClinicMarcia Glass, MD, BAMarcia Glass, MD, BATulane University School of Medicine, New Orleans, Louisiana (M.G.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M19-1784 Audio Reading - “Cleveland Clinic” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “Cleveland Clinic” by Marcia Glass, MD, BA Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail I want to make a pileof all the workout pantsand lucky socksand sunglassesThat walk in the hospitalon someone's dador neighboror friend.And leave in a plastic bag.Handed over to adaughteror a landlordor an ex-wife,And bundled upsomewherewhere they don't belong. Author, Article, and Disclosure InformationAffiliations: Tulane University School of Medicine, New Orleans, Louisiana (M.G.)Current Author Address: Marcia Glass, MD, BA; e-mail, [email protected]edu. PreviousarticleNextarticle Advertisement Audio Reading - “Cleveland Clinic” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “Cleveland Clinic” by Marcia Glass, MD, BA Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 1 September 2020Volume 173, Issue 5Page: 341 ePublished: 1 September 2020 Issue Published: 1 September 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Hypokalaemia due to salbutamol overdosage.
Journal: BMJ (1981)

Case reportA 35-year-old woman was admitted for relapse of acute lymphoblastic leukaemia (FAB grade L 2).Full remission had been achieved after 28 months' treatment with OPAL (vincristine, prednisone, doxorubicin, and L-asparaginase (colaspase)).The relapse proved resistant to OPAL, and high-dose combination chemotherapy with TACC (cyclophosphamide 45 mg/kg/day intravenously, cytosine arabinoside (cytarabine) 100 mg/m2/day intravenously in divided dosage 12-hourly, and 6-thioguanine 100 mg/M2 by mouth 12-hourly for four days, with lomustine 200 mg/M2 by mouth on the second day)3 resulted in bone marrow aplasia.Autologous bone marrow transplantation was therefore performed.The period of total aplasia was complicated by septicaemia (Klebsiella aerogenes), which was treated with intravenous broad-spectrum antibiotics (gentamicin 240 mg and cefuroxime 6 g daily for three weeks and (because of poor response) carbenicillin 30 g/day for two weeks).Intercurrent gastrointestinal candidiasis was treated with antimycotic drugs (miconazole 1-5 g/day by mouth and 1-5 g/day intravenously for four days, and 5-fluorocytosine (flucytosine) 10-0 g/day as continuous intravenous therapy).About three weeks after onset of the septicaemia nausea, vomiting, and right upper abdominal pain appeared.Serum alkaline phosphatase and aspartate and alanine aminotransferase activities remained normal.
Biological Consequences of Environmental Control through Housing
Authors: Douglas H. K. Lee
Journal: Environmental Health Perspectives (1975)

Housing was originally devised as a control of the thermal environment, but numerous other functions have been added with resulting competition and confusion. Current design gives insufficient attention to thermal factors and relies upon supplementary heating and cooling to compensate for faults. These are wasteful of energy, and the exhaust from air conditioners adds to the heat island conditions in city cores. The impact of consumerism on domestic space and the importance of personal space and privacy are reviewed.
Insect Repellents
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
British Association of Dermatologists’ guidelines for the investigation and management of generalized pruritus in adults without an underlying dermatosis, 2018
Authors: G.W.M. Millington, A. Collins, C.R. Lovell, T.A. Leslie, A.S.W. Yong, J.D. Morgan, T. Ajithkumar, M.J. Andrews, S.M. Rushbook, R.R. Coelho, S.J. Catten, K.Y.C. Lee, A.M. Skellett, A.G. Affleck, L.S. Exton, M.F. Mohd Mustapa, N.J. Levell
Journal: British Journal of Dermatology (2018)

Pruritus (or itch) is a common and distressing symptom of many skin diseases, systemic illnesses and psychological disorders. Itch is perhaps the commonest presenting symptom of skin disorders. In any two week period, 8 to 9% of the population suffer from significant pruritus. The focus of this guideline is not itchy rashes, but rather the situation where itch is present without rash. The guidelines also do not cover itch in children, in pregnancy, nor do they detail the science of the cause of itch. The study group consist mostly of dermatologists (skin specialists) from a number of hospitals in the U.K., but a number of other hospital doctors, a nurse and a general practitioner (GP) are also part of the team. There may be an underlying cause of pruritus, such as blood disorders, iron deficiency or excess, kidney problems, liver problems, cancer, infections, medications, behavioural factors, dry skin or any combination of these with old age. This can be significant in 20 to 30% of cases of itchy skin without rash. There remain a small number of individuals with itch and no apparent underlying cause or rash. It is always important to look for an underlying causative condition, as the most effective management of pruritus without rash depends on the treatment of any underlying disease. The management of itch appears to be very situation specific, even if the underlying cause cannot be treated. The management of true pruritus of unknown cause is different again.
STATE SICKNESS AND INVALIDITY INSURANCE
Authors: E. R. Fothergill
Journal: BMJ (1910)

<h3>Objective</h3> To determine visual field (VF) rates of change among patients with glaucomatous VF loss and proportion of those becoming blind based on residual life expectancy and factors associated with fast progression. <h3>Methods and analysis</h3> This was a retrospective study of the VFs of patients with glaucomatous VF defects in at least one eye. Baseline and final VFs were reviewed. Rates of VF change (decibels (dB)/year) for each eye, together with the residual life expectancy based on age and sex, were used to predict mean deviation/defect (MD) at the end of expected lifetime. Blindness was defined if computed MD was 22 dB (Octopus) or −22 dB (Humphrey) or worse in the better eye. Factors associated with fast progression (&gt;1 dB/year for Octopus or &lt;−1 dB/year for Humphrey) and blindness were determined. <h3>Results</h3> There were 1016 eyes of 583 patients eligible. There was decline in VF MD/year in 613/1016 (60.3%), 95% CI (57.3% to 63.3%) of eyes; however, only 98/1016 (9.7%), 95% CI (7.9% to 11.5%) of eyes showed fast progression. Among patients with bilateral VFs, 43/433 (9.9%), 95% CI (7.1 to 12.8) of eyes were predicted to progress to blindness. In multivariate analysis, factors associated with fast progression were baseline MD (p&lt;0.001) and male sex (p=0.041). Factors associated with blindness were age &lt;60 years (p=0.003), baseline MD (p=0.022), bilateral glaucomatous VF defects (p=&lt;0.001) and fast progression (p&lt;0.001). <h3>Conclusion</h3> Patients reaching blindness in a routine clinical setting was 10%. Because of association of age and baseline MD on blindness, early disease detection is important. VF progression rates and residual life expectancy must be incorporated in glaucoma care.